Table 2.

Patient treatment information

Treatment methods	Regimen	PFS (months)	Adverse events (Grade)
First generation EGFR TKI	Gefitinib	18.3	Rash (II)
Third generation EGFR TKI	Osimertinib	11.6	Rash (II); Skin hyperpigmentation (I)
Third generation EGFR TKI + radioactive particles implantation	Osimertinib + particles implantation	2.1	Rash (II)
Third generation EGFR TKIs + first generation ALK TKIs	Osimertinib + crizotinib	6.0	Rash (II); paronychia (II)
Third generation EGFR TKIs + second generation ALK TKIs	Osimertinib + brigatinib	NA	Interstitial penumonia (IV)
Third generation EGFR TKIs + chemotherapy + antiangiogenic therapy	Osimertinib + pemetrexed/carboplatin + bevacizumab	4.2	Rash (II); Asymptomatic, absolute decrease in LEVF (44%)
Chemotherapy + antiangiogenic therapy	Pemetrexed/carboplatin + bevacizumab	16.8 (last CT scan: SD)	Anemia (II)